TheraRadar
← Back
Data updated: Jun 28, 2026

Lupin

Generics
CardiovascularInfectious DiseaseRespiratory Execution: Fair

Lupin is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Respiratory. Key products include LAMIVUDINE AND ZIDOVUDINE.

1998
Since
236
Drugs
-
Trials
4
New Drugs (2yr)
Modality:
3 Small Molecules

Lupin at a Glance

  • Fast trial execution (7 months median completion)

Lupin's Recent FDA Approvals

Lupin secured 4 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

RANLUSPEC BLA
2026-06-02
ranibizumab-hkdz
DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride
ARMLUPEG BLA
2025-11-28
pegfilgrastim-unne
Febrile Neutropenia
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

Lupin's Therapeutic Areas

Lupin's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 31%
20 drugs
Infectious Disease 22%
13 drugs Phase 3: 1 Phase 1: 1
Respiratory 18%
10 drugs Phase 3: 2
Dermatology 16%
10 drugs
Neurology 14%
9 drugs

Lupin Pipeline Snapshot

Lupin has 4 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 0 Phase 2 and 1 Phase 1.

3
Phase 3
0
Phase 2
1
Phase 1

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q1 2027
Granular powder in unit dose foil-lined sachet Mexiletine (PR)
Myotonia
Estimated · aging NCT07097701
Q2 2028
Mexiletine granules for prolonged-release oral suspension
Myotonic Dystrophy
Estimated · fresh NCT06549400

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/6 completed
  • • Speed: 7 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges